argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.
| Revenue (Most Recent Fiscal Year) | $2.25B |
| Net Income (Most Recent Fiscal Year) | $833.04M |
| PE Ratio (Current Year Earnings Estimate) | 41.26 |
| PE Ratio (Trailing 12 Months) | 71.24 |
| PEG Ratio (Long Term Growth Estimate) | 0.76 |
| Price to Sales Ratio (Trailing 12 Months) | 12.96 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 222.80 |
| Pre-Tax Margin (Trailing 12 Months) | 21.24% |
| Net Margin (Trailing 12 Months) | 40.98% |
| Return on Equity (Trailing 12 Months) | 21.06% |
| Return on Assets (Trailing 12 Months) | 18.25% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.73 |
| Book Value per Share (Most Recent Fiscal Quarter) | $99.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $3.74 |
| Earnings per Share (Most Recent Fiscal Year) | $2.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $19.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 61.20M |
| Free Float | 59.71M |
| Market Capitalization | $40.50B |
| Average Volume (Last 20 Days) | 0.43M |
| Beta (Past 60 Months) | 0.39 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.43% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.32% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |